Risk of incident renal cell carcinoma in patients with type 2 diabetes on sodium-glucose co-transporter-2 inhibitor users: a population-based cohort study

被引：0
|
作者：
Jong, G. P. [1 ]
Yang, T. Y. [2 ]
机构：
[1] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan
[2] Chung Shan Med Univ Hosp, Taichung, Taiwan
来源：
EUROPEAN HEART JOURNAL | 2023年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study
    Eroglu, Talip E.
    Coronel, Ruben
    Souverein, Patrick C.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (04) : 289 - 295
  • [32] Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules
    Kim, Jin Hee
    Ko, Hae Young
    Wang, Hye Jin
    Lee, Hyangkyu
    Yun, MiJin
    Kang, Eun Seok
    DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 373 - 382
  • [33] Evaluation of the safety of sodium-glucose co-transporter-2 inhibitors for treating patients with type 1 diabetes
    Wang, Weihao
    Zhang, Lina
    Pei, Xiaobei
    Pan, Qi
    Guo, Lixin
    DIABETES OBESITY & METABOLISM, 2020, 22 (10): : 1767 - 1776
  • [34] The Impact of Sodium-Glucose Co-Transporter-2 Inhibition on Insulin Resistance and Inflammation in Patients with Type 2 Diabetes: A Retrospective Study
    Iordan, Liana
    Lazar, Sandra
    Timar, Romulus
    Popescu, Simona
    Sorescu, Teodora
    Albai, Oana
    Braha, Adina
    Timar, Bogdan
    Gaita, Laura
    MEDICINA-LITHUANIA, 2025, 61 (02):
  • [35] Sodium-glucose co-transporter 2 inhibitors and the risk of acute kidney injury: A population-based cohort study
    Alkabbani, Wajd
    Zongo, Arsene
    Eurich, Dean
    Shah, Baiju
    Minhas-Sandhu, Jasjeet K.
    Alsabbagh, Wasem
    Gamble, John-Michael
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 401 - 401
  • [36] Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry
    Wittbrodt, Eric
    Chamberlain, David
    Arnold, Suzanne V.
    Tang, Fengming
    Kosiborod, Mikhail
    DIABETES OBESITY & METABOLISM, 2019, 21 (08): : 1985 - 1989
  • [37] USE OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITOR IS ASSOCIATED WITH LOW RISK OF HEPATIC DECOMPENSATIONS BUT IS NOT AFFECTING DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN TYPE II DIABETES PATIENTS.
    Kim, Heaeun
    Kim, Jin-Wook
    Park, Jaewon
    Jang, Sangmi
    Jeong, Chan Young
    Choi, Gwang Hyeon
    Jang, Eun Sun
    Jeong, Sook-Hyang
    HEPATOLOGY, 2021, 74 : 1127A - 1128A
  • [38] Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus
    Zhang, Hong
    Zhu, Xiaoxue
    Li, Xiaojiao
    Chen, Hong
    Wu, Min
    Li, Cuiyun
    Liu, Jingrui
    Liu, Chengjiao
    Zhang, Yingjun
    Ding, Yanhua
    DIABETES OBESITY & METABOLISM, 2020, 22 (02): : 191 - 202
  • [39] Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men
    Radholm, Karin
    Zhou, Zien
    Clemens, Kristin
    Neal, Bruce
    Woodward, Mark
    DIABETES OBESITY & METABOLISM, 2020, 22 (02): : 263 - 266
  • [40] Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
    Washburn, William N.
    Poucher, Simon M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (04) : 463 - 486
12345